Table 2.
Prevalence of the infections.
| Total n/N (%, 95 % CI) |
LA n/N (%, 95 % CI) |
SSA n/N (%, 95 % CI) |
NA n/N (%, 95 % CI) |
Other areas of birth n/N (%, 95 % CI) |
p-value* | |
|---|---|---|---|---|---|---|
| T.cruzi infection+ | 14/192 (7.3, 3.6–11.0) | 14/192 (7.3, 3.6–11.0) | – | – | – | – |
| S.stercoralis infection | 7/271 (2.6, 0.7–4.5) | 6/198 (3.0, 0.6–5.4) | 1/38 (2.6, 0.0–8.0) | 0/9 | 0/26 | 1.000 |
| – | – | |||||
| HIV | 5/281 (1.8, 0.2–3.3) | 2/204 (1.0, 0.0–2.3) | 2/40 (5.0, 0.0–12.1) | 0/9 | 1/28 (3.6, 0.0–10.9) | 0.157 |
| – | ||||||
| Chronic HBV (HBsAg +, HBc +) | 5/281 (1.8, 0.2–3.3) | 0/205 | 4/39 (10.3, 0.3–20.2) | 0/9 | 1/28 (3.6, 0.0–10.9) | 0.001 |
| – | ||||||
| – | ||||||
| Exposure to HBV (HBsAg ±, HBc +) | 40/284 (14.1, 10.0–18.2) | 4/207 (1.9, 0.0–3.8) | 30/41 (73.2, 59.0–87.3) | 0/8 | 6/28 (21.4, 5.2–37.6) | <0.001 |
| – | ||||||
| HCV | 1/284 (0.4, 0.0–1.0) | 0/207 | 1/41 (2.4, 0.0–7.4) | 0/9 | 0/27 | 0.271 |
| – | – | – |
LA: Latin America and the Caribbean, SSA: Sub-Saharan Africa, NA: Northern Africa, HIV: Human immunodeficiency virus, HBV: Hepatitis B virus, HBsAg: Australian antigen, HCV: Hepatitis C virus;.
Schistosomiasis was excluded due to the absence of identified cases.
+
Only people from endemic areas of Latin-America were tested for T.cruzi.
⁎
p-values of the bivariate analysis with Pearson's chi-square test or Fisher's exact test.